Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDNG8F)

• Drug Name: 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine Drug Info
• Synonyms: SCHEMBL6660879

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44387948
  TTD Drug ID: DMDNG8F

Molecule-Related Drug Atlas

Drug(s) Targeting Extracellular signal-regulated kinase 1 (ERK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[2]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[5]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ASN007	DMYHEUA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[9]

Drug(s) Targeting Raf messenger RNA (Raf mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN2480	DMBR8NF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
SPN-803	DM8O2AQ	Parkinson disease	8A00.0	Phase 1	[10]
LXH254	DMQE9PS	Non-small-cell lung cancer	2C25.Y	Phase 1	[8]
ICo-007	DM79W8K	Diabetic macular edema	9B71.02	Phase 1	[12]
LErafAON	DMNHPOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
DEBROMOHYMENIALDISINE	DMDLER8	Discovery agent	N.A.	Investigative	[14]
ZM-336372	DMD5JYQ	Discovery agent	N.A.	Investigative	[15]
PLX-ORI3	DMZG1L5	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]
6-Benzylsulfanyl-9H-purine	DMI7FNZ	Discovery agent	N.A.	Investigative	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular signal-regulated kinase 1 (ERK1)	TT1MG9E	MK03_HUMAN	Inhibitor	[1]
Raf messenger RNA (Raf mRNA)	TTAN5W2	RAF1_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
• [2] DOI: 10.1158/1538-7445.AM2015-4693
• [3] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [4] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [5] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [6] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [7] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
• [11] Clinical pipeline report, company report or official report of Roche.
• [12] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [13] Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
• [14] Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
• [15] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.